Hasenkamp, Justin

[["dc.bibliographiccitation.firstpage","2438"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","2447"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Ritgen, Matthias"],["dc.contributor.author","Boettcher, Sebastian"],["dc.contributor.author","Busch, Raymonde"],["dc.contributor.author","Dietrich, Sascha"],["dc.contributor.author","Bunjes, Donald W."],["dc.contributor.author","Cohen, Sandra"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Hegenbart, Ute"],["dc.contributor.author","Beelen, Dietrich"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Uharek, Lutz"],["dc.contributor.author","Scheid, Christof"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Zenz, Thorsten"],["dc.contributor.author","Winkler, Dirk"],["dc.contributor.author","Hallek, Michael"],["dc.contributor.author","Kneba, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Stilgenbauer, Stephan"],["dc.date.accessioned","2018-11-07T08:38:06Z"],["dc.date.available","2018-11-07T08:38:06Z"],["dc.date.issued","2010"],["dc.description.abstract","The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/cyclophosphamide-based. Longitudinal quantitative monitoring of minimal residual disease (MRD) was performed centrally by MRD-flow or real-time quantitative polymerase chain reaction. One hundred eligible patients were enrolled, and 90 patients proceeded to alloSCT. With a median follow-up of 46 months (7-102 months), 4-year nonrelapse mortality, event-free survival (EFS) and overall survival (OS) were 23%, 42%, and 65%, respectively. Of 52 patients with MRD monitoring available, 27 (52%) were alive and MRD negative at 12 months after transplant. Four-year EFS of this subset was 89% with all event-free patients except for 2 being MRD negative at the most recent assessment. EFS was similar for all genetic subsets, including 17p deletion (17p-). In multivariate analyses, uncontrolled disease at alloSCT and in vivo T-cell depletion with alemtuzumab, but not 17p-, previous purine analogue refractoriness, or donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS. In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile. This trial is registered at http://clinicaltrials.gov as NCT00281983. (Blood. 2010;116(14):2438-2447)"],["dc.description.sponsorship","Roche; Novartis; Bayer; Amgen; Celgene; Glaxo Smith-Kline"],["dc.identifier.doi","10.1182/blood-2010-03-275420"],["dc.identifier.isi","000282645900010"],["dc.identifier.pmid","20595516"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18693"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:52:41Z"],["dc.date.available","2018-11-07T10:52:41Z"],["dc.date.issued","2007"],["dc.format.extent","894A"],["dc.identifier.isi","000251100804080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49168"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Intermediate intensity conditioning followed by allogeneic peripheral blood stem cell transplantion for treatment of high risk relapse of aggressive lymphoma. Interim analysis of the DSHNHL R3 study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","757"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The Lancet Oncology"],["dc.bibliographiccitation.lastpage","766"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2021-06-01T10:50:22Z"],["dc.date.available","2021-06-01T10:50:22Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1016/S1470-2045(14)70161-5"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86631"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","1470-2045"],["dc.title","Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","397"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Nickelsen, M."],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:45:48Z"],["dc.date.available","2018-11-07T10:45:48Z"],["dc.date.issued","2004"],["dc.description.abstract","In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P = 0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL."],["dc.identifier.doi","10.1038/sj.bmt.1704600"],["dc.identifier.isi","000223351200002"],["dc.identifier.pmid","15273707"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47591"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0268-3369"],["dc.title","Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T09:10:20Z"],["dc.date.available","2018-11-07T09:10:20Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009803810"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26463"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","877"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2020-12-10T18:09:41Z"],["dc.date.available","2020-12-10T18:09:41Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41409-018-0360-9"],["dc.identifier.eissn","1476-5365"],["dc.identifier.issn","0268-3369"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73726"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T11:21:57Z"],["dc.date.available","2018-11-07T11:21:57Z"],["dc.date.issued","2009"],["dc.format.extent","1312"],["dc.identifier.isi","000272725804044"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55894"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","51st Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","689"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","690"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T11:09:03Z"],["dc.date.available","2018-11-07T11:09:03Z"],["dc.date.issued","2008"],["dc.identifier.isi","000262104702307"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52925"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","0006-4971"],["dc.title","Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]